Efforts to develop clinically effective cell-specific drug-delivery technology have not as yet been successful. This prospective review gives and analyzes reasons for the lack of progress in this area, and argues that the use of antibodies as drug carriers offers the best currently available approach. For this approach to work, drugs to be delivered must exhibit the pharmacokinetic properties matching the essential requirements of cellspecific drug delivery. Examples from targeting cancer drugs are used.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : July 20, 2019